All In Biotech

Drug Trial Radar · NCT00286208

Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation

A Randomized Study of Sublingual Versus Oral Misoprostol Administration Following Mifepristone 200 mg for Abortion up to 63 Days Gestation

Last checked: Nov 20, 2026Latest source record: Feb 19, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,443 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,443

Actual

Start

Aug 2005

Primary completion

Jan 2008

Study completion Jan 2008

Sponsor

Lead sponsor
Gynuity Health ProjectsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 3, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This open-label, randomized study is being conducted to determine whether a dose of 400 mcg of sublingual misoprostol (i.e., under the tongue) taken 24 hours following administration of mifepristone 200 mg is effective and acceptable at inducing an abortion compared with misoprostol taken orally. The goal of this study is to provide answers to the following four questions: 1. Is a regimen of medical abortion with mifepristone using sublingual misoprostol at least as effective as using oral misoprostol up to 63 days since the last menstrual period (LMP)? 2. Are the side effects with sublingual use tolerable for women? 3. Is sublingual administration of misoprostol acceptable to women? 4. Is one of the regimens (sublingual or oral) superior in terms of efficacy, safety (side-effects) or acceptability?

Conditions

  • Induced Abortion

Interventions

  • Mifepristone, misoprostolDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Need for surgical completion for incomplete abortions or ongoing viable pregnancies at follow up visit Study day 15.Time frame: 2 weeks after mifepristone administration

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • State University of Medicine and Pharmacy

    Chisinau, Moldova

  • Centre de Planification Familiale de l'Ariana

    Aryanah, Tunisia

  • Centre de Planification Familiale la Bardo

    Tunis, Tunisia

  • Maternité de La Rabta

    Tunis, Tunisia

  • Private clinic

    Tunis, Tunisia

  • Dr. Zekai Tahir Burak Women's Health Training and Research Hospital

    Ankara, Turkey (Türkiye)

  • MoH Ankara Etlik Maternity and Gyneacological Training Hospital

    Ankara, Turkey (Türkiye)

  • Haydarpaşa Numune Training and Research Hospital Family Planning Clinic

    Istanbul, Turkey (Türkiye)

  • Ege Maternity and Gyneacological Training and Research Hospital

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.